[CAR T-cell therapy in rheumatology-What we know so far?] / CAR-T-Zell-Therapie in der Rheumatologie Was wissen wir bisher?
Z Rheumatol
; 83(6): 485-491, 2024 Aug.
Article
en De
| MEDLINE
| ID: mdl-38780637
ABSTRACT
Autoreactive Bcells play a key role in the pathogenesis of autoimmune diseases, such systemic lupus erythematosus (SLE). An efficient depletion of Bcells therefore plays a special role in autoimmune diseases, especially in cases with a severe course of the disease. Treatment with chimeric antigen receptor (CAR) Tcells, which was originally developed for the treatment of Bcell lymphomas and leukemias, provides the possibility to deplete Bcells even in deep tissues. The initial results from case series with this procedure for SLE, myositis and systemic sclerosis were very positive. This review article gives an overview of the course, mechanism of action, results so far and the research agenda of CAR Tcell therapy in autoimmune diseases.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Inmunoterapia Adoptiva
Límite:
Humans
Idioma:
De
Revista:
Z Rheumatol
Año:
2024
Tipo del documento:
Article